Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models

Roland Hubaux¹,²,³,⁴, Fabian Vandermeers¹,²,³,⁴, Jean-Philippe Cosse¹,², Cecilia Crisanti⁴, Veena Kapoor⁴, Steven M. Albelda⁶, Céline Mascaux⁵, Philippe Delvenne⁶, Pascale Hubert⁶ and Luc Willems¹,²,³

Affiliations: ¹Molecular Biology (GxABT), University of Liege (ULg), Gembloux, Belgium. ² Molecular and Cellular Epigenetics (GIGA), ULg, Liege, Belgium. ³Interdisciplinary Cluster for Applied Genoproteomics (GIGA), ULg, Liege, Belgium. ⁴Pulmonary, Allergy and Critical Care Division, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA. ⁵Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University, Marseille, France. ⁶Experimental Pathology, GIGA-Cancer, ULg, Liège, Belgium.

Correspondence: Luc Willems, National Fund for Scientific Research at ULg, Molecular and Cellular Epigenetics, Interdisciplinary Cluster for Applied Genoproteomics (GIGA) [Bldg 34], n°1 allée de l’Hôpital, Sart-Tilman, 4000 Liège, Belgium. E-mail: luc.willems@ulg.ac.be

ABSTRACT With 5-year survival rates below 5%, small cell lung carcinoma (SCLC) has very poor prognosis and requires improved therapies. Despite an excellent overall response to first-line therapy, relapses are frequent and further treatments are disappointing. The goal of the study was to improve second-line therapy of SCLC.

The effect of chemotherapeutic agents was evaluated in cell lines (apoptosis, reactive oxygen species, and RNA and protein expression) and in mouse models (tumour development).

We demonstrate here that valproic acid, a histone deacetylase inhibitor, improves the efficacy of a second-line regimen (vindesine, doxorubicin and cyclophosphamide) in SCLC cells and in mouse models.

Transcriptomic profiling integrating microRNA and mRNA data identifies key signalling pathways in the response of SCLC cells to valproic acid, opening new prospects for improved therapies.

This article has supplementary material available from openres.ersjournals.com

Received: June 02 2015 | Accepted after revision: Aug 24 2015

Support statement: The work was supported by the Fonds National de la Recherche Scientifique (FNRS), the Télévie, the Interuniversity Attraction Poles programme BELVIR initiated by the Belgian Science Policy Office, the Action de Recherche Concertée Glyvir of the Communauté française de Belgique, the Belgian Foundation against Cancer, the Sixth Research Framework Programme of the European Union (project INCA LSHC-CT-2005-018704), the Neoangio excellence programme and the Partenariat Public Privé INCA of the Direction générale des Technologies, de la Recherche et de l’Energie/DG06 of the Walloon government, the Centre anticancéreux près ULg, the Synbiofor and AgricultureLife projects of GxABT, the ULg Fonds Spéciaux pour la Recherche, the Plan Cancer of the Service Public Fédéral. L. Willems (research director) is member of the FNRS. Funding information for this article has been deposited with FundRef.

Conflict of interest: Disclosures can be found alongside this article at openres.ersjournals.com

The content of this work is ©the authors or their employers. Design and branding are ©ERS 2015. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Introduction

Lung cancer is the leading cause of cancer-related death worldwide. The outcome of small cell lung carcinoma (SCLC) patients is the poorest of any histological subtype, with 5-year survival rates of <25% and <5% for limited- and extensive-stage disease, respectively [1]. Despite overall first-line response rates ranging between 60% and 80% (extensive), and 80% and 90% (limited), most tumours relapse. The prognosis remains very poor, with median survival rates of only 8–13 months (extensive) and 14–20 months (limited) [2]. Although significant efforts to develop new therapeutic strategies have been made during the last decade, results are still disappointing [2–5]. Future improvements in outcomes will require clarification of the molecular basis of this disease [1].

Epigenetic errors contribute to the initiation, progression and response to therapy of cancer (reviewed by Barnes et al. [6] and Petta et al. [7]). We and others previously proposed a working hypothesis postulating that histone deacetylase (HDAC) inhibitors induce antitumor activity by reversing epigenetic errors [8–11]. In particular, valproic acid (VPA) is an inhibitor of HDACs displaying appropriate pharmacokinetic properties, and yielding only moderate toxicity that is acceptable in the context of an anticancer treatment [12–14]. By modulating a broad range of activities, including proliferation, apoptosis and differentiation, VPA has antitumoural properties in several cancers, including SCLC [15–21].

Although there is no standard second-line therapy for SCLC, possible treatments most often comprise a combination of three chemotherapeutic agents: a DNA crosslinking agent (e.g. cyclophosphamide), an inhibitor of topoisomerase II (e.g. doxorubicin) and a mitotic spindle poison (e.g. vindesine) (here referred to collectively as “VAC”). With the aim of improving the treatment of extensive SCLC, we evaluated the capacity of VPA to increase the anticancer effect of the VAC regimen in cell cultures and in xenograft mouse models. The mechanisms involved in chemotherapeutic response to VPA were then studied by transcriptomic analyses.

Materials and methods

Cell culture conditions

Human SCLC cell lines (H146, H526 and H69) were purchased from the ATCC (Manassas, VA, USA) and cultivated as detailed previously [19]. Cells were incubated with VPA (Sigma-Aldrich, Diegem, Belgium), mafosfamide (Baxter, Braine-l’Alleud, Belgium), cyclophosphamide (Baxter), doxorubicin (Pfizer, Elsene, Belgium) and vindesine (Lilly, Brussels, Belgium), alone or in combination. Since cyclophosphamide needs to be activated in vivo by the hepatic metabolism, its active form, mafosfamide, was used for in vitro experiments. Optimal drug concentrations were determined by MTS viability assays.

Detection of apoptosis

Apoptosis was quantified by flow cytometry after ethanol fixation and propidium iodide incorporation, as outlined previously [22]. A synergy index was calculated using the formula:

\[
\text{Synergy index} = \frac{\text{specific apoptosis upon combined treatment}}{\text{sum of specific apoptosis of single agent treatment}}
\]

The percentage of specific apoptosis was determined using the formula:

\[
\text{Specific apoptosis} = \frac{\text{drug induced apoptosis} - \text{spontaneous apoptosis}}{100 - \text{spontaneous apoptosis}} \times 100\%
\]

When the synergy index was >1, 1 or <1, the effects were defined as synergistic, additive or antagonistic, respectively.

To assess the role of caspases in apoptotic pathways, 5×10^5 cells were incubated with or without: 20 μM Z-Val-Ala-Asp(OMe)-CH₂F (Becton Dickinson, Erembodegem, Belgium), a total pan-caspase inhibitor; 20 μM negative control (Z-FA-fmk) (Becton Dickinson); 40 μM Z-Ile-Glu(OMe)-Thr-Asp(OMe)-CH₂F (Calbiochem, Overijse, Belgium), a caspase-8 specific inhibitor; or 40 μM Z-Leu-Glu(OMe)-His-Asp(OMe)-CH₂F (Calbiochem), caspase 9 specific inhibitor; all compounds being diluted in dimethylsulfoxide.

Quantification of reactive oxygen species

Reactive oxygen species (ROS) were detected using 5,6-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate acetyl ester (CM-H₂DCFDA; InVitrogen, Ghent, Belgium). After 30 min of pre-incubation with 5 μM CM-H₂DCFDA, the different drugs were added alone or in combination. After 24 h of culture,
SCLC cell lines (5×10⁵ cells per mL in 24-well plates) were harvested, washed with PBS and analysed by flow cytometry (FACS Aria; Becton Dickinson). ROS production was quantified using the fluorescence intensity of chloromethyldichlorofluorescein. 10000 events were collected and analysed with the FACS Diva software (Becton Dickinson). Cells were also treated with 100 μM hydrogen peroxide or 10 mM N-acetylcysteine (Calbiochem), a free-radical scavenger, as positive and negative controls, respectively.

**Immunoblot analysis**
Protein expression levels and intracellular translocations were assessed using cytosolic and nucleic buffers, and standard protocols for western blotting as detailed previously [19]. The antibodies used were: anti-acetylated histone H3 (Upstate, Upstate, Belgium), anti-actin, anti-Erk (both Sigma-Aldrich), anti-Bax, anti-Bcl-2 (both Dako Cytomation, Heverlee, Belgium), anti-Bid, anti-cytochrome c (Becton Dickinson), anti-BclXL, anti-phospho-Erk, anti-caspase 8, anti-caspase 9 (Cell Signaling, Leiden, the Netherlands), anti-γH2AX and anti-VDAC1 (Abcam, Cambridge, UK).

**Evaluation of regimen efficacy in severe combined immunodeficiency mice**
The Institutional Animal Care and Usage Committee of the University of Pennsylvania (Philadelphia, PA, USA) and the University of Liege (Liege, Belgium) approved all animal protocols in compliance with the Guide for the Care and Use of Laboratory Animals, according to the Declaration of Helsinki. The severe combined immunodeficiency (SCID) mice (BALB/c HanHsd-Prkdc; Jackson Laboratories, Sacramento, CA, USA) or NOD/SCID mice received a standard research diet throughout the experiment. H146 and H69 cells (2×10⁶), embedded in 50% Matrigel Basement Membrane Matrix High Concentration (BD Biosciences, Erembodegem, Belgium), were implanted subcutaneously into the flanks of 7-week-old female SCID mice. When tumours reached a volume of 300–400 mm³, mice were administered with daily intraperitoneal injections of VPA (400 mg·kg⁻¹·day⁻¹) or PBS as a control. 3 days after the first VPA administration, intraperitoneal injections of cyclophosphamide (40 mg·kg⁻¹), vindesine (0.5 mg·kg⁻¹) and doxorubicin (3 mg·kg⁻¹) were performed (at days 14 and 17, and days 8, 13, 25 and 34 for H69 and H146, respectively). The schedule of drugs injections was first determined in preliminary dose response experiments. Tumour volumes were calculated twice a week using the formula:

\[ \text{Tumour volume} = \frac{\pi D d^2}{6} \]

where \( D \) is the largest diameter and \( d \) the smallest. Groups of at least six mice were tested under each experimental condition.

**RNA extraction**
Cell lines were cultivated for 4 h in presence of 1 mM VPA. RNA was then extracted after two washes in PBS and lysis Trizol RNA Isolation Solution (Ambion, Ghent, Belgium), according to the manufacturer’s protocol. For microarray analysis, a second separation between the aqueous and organic phases was performed on Phase Lock Gel (5 Prime, Leuven, Belgium) to optimise RNA recovery and purity. All the extracted RNAs were assessed for quantity and purity using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Temse, Belgium) and stored at −80°C until the amplification step.

**Microarray analysis**
The details of the microarray analysis have been described previously [19]. Briefly, reference RNAs were obtained by pooling equal amounts of total RNAs from three different SCLC cell lines (H146, H526 and H69). RNAs were reverse-transcribed with Moloney murine leukaemia virus reverse transcriptase using a polydeoxythymidine primer and amplified by PCR. The cDNAs were transcribed into copy RNAs (cRNAs) transcribed and labelled with Cy3 (reference) or Cy5 (sample) dyes using the Low Input RNA Linear Amplification Plus kit (Agilent Technologies, Diegem, Belgium). After quality checking, the labelled cRNAs and RNAs spiked in were hybridised on an Agilent oligonucleotide microarray (two-colour Whole Human Genome 4×44K arrays) and analysed according to manufacturer’s protocol (GE2_v5_95_Feb07; Feature Extraction software, version 9.5.3.1). The statistical analyses were performed with Genespring GX, version 7.3.1 (Agilent Technologies). Additional normalisation steps were performed (per spot: division by the control signal; per array: normalisation to the 50th centile; per gene: normalisation to the median). Transcripts that were not present in at least one sample were excluded from additional analyses. Welch’s t-test was used to assess the statistical significance, excluding genes whose expression varied by a factor inferior to 2 across the sample set of interest. The threshold for statistical significance after Benjamin’s correction for multiple testing was 0.05.
Real-time reverse transcription PCR

mRNA levels were analysed by real-time quantitative reverse transcription PCR (qRT-PCR) as described previously [19], using the primers in table 1.

MicroRNA analysis

MicroRNA (miRNA) expression was determined in triplicates using the TaqMan Low Density Array method (DNANvision, Gosselies, Belgium). Fluorescence data (Bioanalyzer 2100 Nano chip; Agilent Technologies) were normalised by means of two endogenous controls (RNU44 and RNU48). Results were expressed as fold change (2^\((-\Delta\Delta CT(VAC+VPA)/\Delta\Delta CT(VAC))\), where CT is the cycle threshold). The Benjamini and Hochberg method was used for multiple testing corrections.

Statistical analysis

All cell culture experiments were performed at least three times and data are presented as mean± SD. Statistical significance was calculated using Student's t-test and data were considered statistically significant, very statistically significant or highly statistically significant when p<0.05, p<0.01 and p<0.001, respectively.

Results

VPA increases apoptosis in SCLC cells treated with VAC in vitro and in vivo

To evaluate the synergism between VPA and the second-line regimen VAC, VPA, at a concentration achievable in patients (1 mM) [23], was combined with therapeutically relevant doses of mafosfamide (10 μM), doxorubicin (0.3 μM) and vindesine (20 nM). After 24 h of culture, the combination of VPA and VAC significantly increased apoptotic rates in three SCLC cell lines (H146, H69 and H526; p<0.01 by Student’s t-test) (figure 1). In fact, the effect of VPA on the combined VAC treatment was synergistic (synergy index of 2.9, 2.4 and 1.6 in H146, H69 and H526 cells, respectively).

We next determined the involvement of specific caspases using pharmacological inhibitors of caspases 3, 8 and 9 (figure 2). To facilitate comparison between treatments, control results (Z-FA-fmk) were arbitrarily normalised to 1. All three inhibitors significantly reduced apoptosis of SCLC cells, indicating that the mechanism is caspase-dependent, and involves both extrinsic and intrinsic pathways.

To evaluate the role of reactive oxygen species in the apoptotic process, intracellular ROS levels were monitored by flow cytometry in H146, H69 and H526 cells cultivated for 24 h in presence of VPA and/or VAC. VPA, but not VAC, significantly increased ROS production in all three cell lines (p<0.05) (figure 3a, c and e). Despite significantly decreasing ROS levels, the free-radical scavenger N-acetylcysteine was not sufficient to inhibit apoptosis (figure 3b, d and f).

### Table 1: Real-time quantitative reverse transcription PCR primers

| Target   | Forward primer                         | Reverse primer                         |
|----------|----------------------------------------|----------------------------------------|
| BAG3     | 5'-ACAACAGCAGCCACACACTAC-3'            | 5'-GAAGCAGAGAAAATGGAAGATG-3'           |
| BBC3     | 5'-CTCAGGACTCTGCTAATCTA-3'             | 5'-GCACCTAATGGGTCCTACATCT-3'           |
| C17orf69 | 5'-AGGGATGTGCTGCTGCTGCTG-3'            | 5'-AGGGATGTGCTGCTGCTGCTG-3'            |
| C18orf4  | 5'-TGAGACCCCAATCAACAGAA-3'             | 5'-CTTGAAGCTCAGATGTGAACAA-3'           |
| C6orf24  | 5'-GGCTGTTTTGCTGCTGCTGCTG-3'           | 5'-TTCGCCGGAATGAAAGATG-3'              |
| C6orf204 | 5'-GAGGAGGAGACGTAGAGATG-3'             | 5'-CAGAGGAGCAGCTGAGATGAAGAA-3'         |
| C6ST     | 5'-AGACCTGATCCGCTGATGCTG-3'            | 5'-TGGCTTTCCTGATGGGCTG-3'              |
| C20orf29 | 5'-TCTGGGTCCTGAAGATGGA-3'              | 5'-CGTAAAGCTCAGCTGAGTGAAGAA-3'         |
| DLH2     | 5'-GCAATGAGGCTCTACCCTACGT-3'           | 5'-TCTGGTCAGCTGCTGCTGCTG-3'            |
| EFL4     | 5'-TTCACCCTCTCCAGCTGAGACG-3'           | 5'-CTGATTGAGGGGGCCAGCACAA-3'           |
| EPH2     | 5'-GACCTTATGGTCTCTTGTCTGC-3'           | 5'-TCCACCTAGATGGTCTCCAAA-3'            |
| FOXO1A   | 5'-AAAGGCCGAGGCTACTCAA-3'              | 5'-CACCCCTGATGAGATGCAC-3'              |
| F207     | 5'-CAAGCCACTGCTTACCGGCTCTC-3'          | 5'-GGCACTCCAGAAGTGATAGGAG-3'           |
| GPRC37   | 5'-GCTAGTTCACTCCTCCTCTG-3'             | 5'-GTGGTCTACCCAGACAGAGGAC-3'           |
| HEY1     | 5'-CGAGGCGAGGAAGGAGACGATG-3'           | 5'-CTGGGTCAAAGCTTCCCTACAG-3'           |
| HPRT     | 5'-GCTGCCAGGACGATATAACAAAACG-3'        | 5'-AACAGCAGCTCCTACCAACAA-3'            |
| HSC40    | 5'-GCCTGGAATACCAACCACA-3'              | 5'-CAAAGAAAGGAGGGGAGCTG-3'             |
| IER5     | 5'-ACAGGTCTGCTCGATTTGTG-3'             | 5'-TCCAGGAGGCTATGCTGCTC-3'             |
| RAB43    | 5'-GGACAGGAGACATCGAGGTTCTC-3'          | 5'-GCAGGAGGCTATGCTGCTGCTG-3'           |
| SLIT     | 5'-GCCACAGAAATCACAAACAAA-3'            | 5'-AAGGGTGATATGCTGCTGCTG-3'            |
| TNFRSF19 | 5'-GCTGAAAGCAGAATCTCCAAAC-3'           | 5'-CGGAAAGACATCATCCTACCAAA-3'          |
| WIP1     | 5'-GCCCTGAGGCTGATGCTAGT-3'             | 5'-TCCAGGAGGCTTCCAGAC-3'               |
We next evaluated expression of a series of proteins involved in the cell cycle and apoptosis (figure 4). Western blot analysis demonstrated that VPA-induced apoptosis involved hyperacetylation of histone H3 and phosphorylation of Erk1/2. Double-stranded DNA breaks in the presence of VPA were revealed by γH2AX blotting. VPA created an imbalance between pro- and anti-apoptotic modulators: a decrease in cytoplasmic Bcl-2 and BclxL; cleavage of Bid (into t-Bid); processing of caspase 8 and caspase 9; the appearance of a cleaved form of Bax in the mitochondria; and release of cytochrome c into the cytoplasm.

Based on the proapoptotic synergy between VPA and VAC in SCLC cells, we investigated the ability of VPA to improve antitumor efficacy in mouse models. Therefore, SCLC cells (H69 and H146) were injected subcutaneously into the flanks of SCID mice, and the mice were treated with VPA, cyclophosphamide
(40 mg·kg⁻¹), doxorubicin (3 mg·kg⁻¹) and vindesine (0.5 mg·kg⁻¹), as described in the materials and methods section. Although partial responses were observed with VPA or VAC, tumours eventually relapsed (figure 5). In contrast, tumour growth was restricted in both SCID mouse xenograft models when VPA was combined with VAC (p<0.001 and p<0.05 by Student's t-test, for H69 and H146, respectively). We conclude that, in two preclinical models of SCLC, VPA improves the efficacy of VAC.

VPA modulates key cellular pathways in SCLC, including cell death and tumour invasion

To better characterise the molecular mechanisms involved, we analysed the transcriptome of H526 cells treated for 4 h with VPA and/or VAC using Agilent microarrays. Bioinformatic analyses revealed a list of genes that were significantly up- or down-regulated by a factor >2 in presence of VPA. Among these, 138 were also specifically identified in cells treated with VPA+VAC compared to VAC (online supplementary material). Expression of the most significantly modulated genes was confirmed by qRT-PCR in three SCLC cell lines (table 2).

With 54 genes involved, cell death was the top scored biological function affected, as revealed by Ingenuity (Qiagen, Venlo, the Netherlands) (figure 6). The network related to this function included several genes involved in apoptosis: BBC3 (Puma, a pro-apoptotic member of the Bcl2 family), TNFRSF19 and TNFRSF12A (upstream effectors of apoptosis). To extend this transcriptomic analysis, we next analysed expression of miRNAs [24, 25]. After correction for multiple testing, only two miRNAs were significantly modulated when
adding VPA, both of them being involved in tumour invasion: miR-589 (fold increase of 441 with VPA, corrected p-value <0.01) and miR-575 (fold decrease of 0.018, corrected p-value <0.05) (table 3).

Discussion
The preclinical evidence provided in this report indicates that VPA synergistically increases the apoptotic rates of three different cell lines in response to a second-line therapy for SCLC (figure 1). The mechanism

![Figure 4](image-url)
is caspase-dependent, and involves both extrinsic and intrinsic pathways (figure 2). VPA increases the level of ROS, and modifies the balance between pro- and antiapoptotic modulators (figures 3 and 4). The new regimen of VPA+VAC efficiently reduces tumour growth in SCID mouse models engrafted with human SCLC cells (figure 5). This evidence spurred the European Lung Cancer Work Party to launch a phase I/II clinical trial to assess the combination of VPA with VAC in patients presenting with relapsing or refractory SCLC.

FIGURE 5 Valproic acid (VPA) prevents small cell lung carcinoma (SCLC) tumour growth in combination with cyclophosphamide, vindesine and doxorubicin. Two human SCLC cell lines (H69 [a] and H146 [b]) were injected subcutaneously into severe combined immunodeficiency mice in 50% matrigel. Groups of at least six mice were tested in each experimental condition. When tumours reached a volume of 300–400 mm³, mice were administered with daily intraperitoneal injections of VPA [400 mg·kg⁻¹·day⁻¹] or PBS as a control. 3 days after the first VPA administration, intraperitoneal injections of cyclophosphamide [40 mg·kg⁻¹], vindesine [0.5 mg·kg⁻¹] and doxorubicin [3 mg·kg⁻¹] were performed (at days 14 and 17, and days 8, 13, 25 and 34 for H69 and H146, respectively [arrows]). The tumour volume [in cubic millimetres] is presented as means±SD and was calculated at regular intervals of time. There is a statistical significant difference according to the Student’s t-test: **: p<0.01 for VAC+VPA versus VAC only treatments.

TABLE 2 The 21 most significantly modulated genes were selected from microarray analysis comparing treatment with valproic acid plus VAC versus VAC alone

| Name     | Common name | Genbank accession number | H69   | H526  | H146  |
|----------|-------------|--------------------------|-------|-------|-------|
| BAG3     | BAG3        | NM_004281                | 2.3   | 2.2   | 2.0   |
| BBC3     | PUMA        | NM_014417                | 2.8   | 5.2   | 2.3   |
| C17orf59 | PRO2472     | NM_017622                | 1.8   | 3.1   | 3.0   |
| C18orf64 | C18orf64    | NM_032160                | 13.8  | 4.2   | 1.3   |
| C20orf29 | FLJ11168    | NM_018347                | 0.3   | 0.4   | 3.6   |
| C6orf24  | C6orf24     | NM_152618                | 10.8  | 4.6   | 2.6   |
| C6orf204 | C6orf204    | BC045657                 | 2.0   | 2.0   | 1.6   |
| C6ST     | C6ST        | NM_004267                | 1.4   | 5.7   | 4.2   |
| DLH2     | TES1        | NM_004405                | 9.1   | 4.1   | 1.0   |
| EFL4     | EFL4        | NM_005227                | 8.7   | 5.4   | 14.3  |
| EPH2     | DKK2P546F2124| NM_015630               | 0.4   | 0.3   | 3.8   |
| FOXO1A   | FOXO1A      | NM_002015                | 4.6   | 3.4   | 67.2  |
| FZD7     | FzD7        | NM_003507                | 3.2   | 17.9  | 7.5   |
| GPCR37   | PAELR       | NM_005302                | 2.1   | 3.6   | 20.0  |
| HEY1     | HERP2       | NM_012258                | 0.7   | 2.4   | 1.9   |
| HSC40    | HSC40       | NM_012266                | 2.0   | 3.4   | 24.9  |
| IER5     | SBB148      | NM_016545                | 1.5   | 1.9   | 4.4   |
| RAB43    | RAB41       | NM_198490                | 10.5  | 5.3   | 6.1   |
| SLIT     | LRRC12      | NM_052910                | 3.3   | 3.4   | 1.8   |
| TNFRSF19 | TROY        | NM_148957                | 1.1   | 2.0   | 3.5   |
| WIP11    | WIP11       | NM_017983                | 1.7   | 2.7   | 1.0   |

Data are fold changes obtained by quantitative reverse transcription PCR of transcripts isolated from three small cell lung carcinoma cell lines (H69, H526 and H146). VAC: mafosfamide, doxorubicin and vindesine.
FIGURE 6 Valproic acid (VPA) modulates expression of genes involved in cell death pathways. Genes transcriptionally modified by VPA extracted from the online supplementary material were analysed with the Ingenuity software. The most significantly affected molecular and cellular function was cell death (p<3.89×10^{-0.5}, with 54 genes modulated: ADRB2, ALX3, ARC, BAG3, BBC3, BCL6, CNN2, CYP26B1, DLL1, DLX2, DUSP10, EGR1, EGR4, EPHA2, FBXO32, FOXO1, G6S2, GDF15, GFI1, GJB2, GPC3, GPR37, HEY1, IER3, IL9R, JAG1, KLF2, KLF5, LATS2, MERTK, MITF, NKX3-2, NRG4, NTF3, NUAK2, PAX6, PPDFRA, PPARA, RASD1, RASSF4, RUNX1, RUNXIT1, S100A10, S6K1, SIRT4, SOCS3, STR2, TNFRSF19, TNFRSF12A, TSLP, USE1, VIPR2, WNT11 and ZFP36). Red and green indicate up- and down-regulated genes, respectively.

TABLE 3 MicroRNAs modulated by valproic acid

| TaqMan target | miRBase number | Fold change | p-value by t-test | Corrected p-value |
|---------------|----------------|-------------|------------------|------------------|
| hsa-miR-589   | hsa-miR-589*   | 441.31735   | 0.000015         | 0.005305         |
| hsa-miR-575   | hsa-miR-575    | 0.01787     | 0.000175         | 0.031945         |
| hsa-miR-200a* | hsa-miR-200a*  | 4.23666     | 0.000108         | 0.112437         |
| hsa-miR-345   | NA             | 5.41671     | 0.000123         | 0.112437         |
| hsa-miR-124a  | hsa-miR-124    | 0.27756     | 0.000231         | 0.120889         |
| hsa-miR-16    | hsa-miR-16     | 0.38224     | 0.000180         | 0.120889         |
| hsa-miR-616   | hsa-miR-616*   | 0.06316     | 0.000215         | 0.120889         |
| hsa-miR-182*  | hsa-miR-182*   | 0.28658     | 0.000347         | 0.154357         |
| hsa-miR-376a* | NA             | 0.04461     | 0.000422         | 0.154357         |
| hsa-miR-130b  | hsa-miR-130b   | 0.46074     | 0.000537         | 0.165957         |
| hsa-miR-9     | hsa-miR-9      | 3.51174     | 0.000546         | 0.165957         |
| hsa-let-7a    | hsa-let-7a     | 3.52777     | 0.000820         | 0.201666         |
| hsa-miR-106b  | hsa-miR-106b   | 0.49053     | 0.000828         | 0.201666         |
| hsa-miR-142-3p| hsa-miR-142-3p | 4.82212     | 0.000763         | 0.201666         |
| hsa-miR-200c  | hsa-miR-200c   | 2.30733     | 0.010624         | 0.212291         |
| hsa-miR-29c   | hsa-miR-29c    | 0.43967     | 0.011632         | 0.212291         |
| hsa-miR-564   | hsa-miR-564    | 4.74989     | 0.011971         | 0.212291         |
| hsa-miR-9*    | hsa-miR-9*     | 0.43287     | 0.010819         | 0.212291         |
| hsa-miR-99b   | hsa-miR-99b    | 0.49626     | 0.011479         | 0.212291         |
| hsa-miR-324-5p| hsa-miR-324-5p | 0.49551     | 0.014315         | 0.237493         |
| hsa-let-7g    | hsa-let-7g     | 2.60556     | 0.017417         | 0.264876         |
| hsa-miR-181b  | hsa-miR-181b   | 2.16330     | 0.019021         | 0.272956         |
| hsa-miR-594   | NA             | 0.40264     | 0.019443         | 0.272956         |
| hsa-let-7d    | hsa-let-7d     | 2.28268     | 0.022429         | 0.303208         |
| hsa-miR-427c  | hsa-miR-427c   | 0.30744     | 0.029794         | 0.362498         |
| hsa-miR-335   | hsa-miR-335    | 0.38050     | 0.038849         | 0.386740         |
| hsa-miR-565   | NA             | 0.40463     | 0.044928         | 0.395449         |
| hsa-miR-99a   | hsa-miR-99a    | 0.45290     | 0.049659         | 0.421521         |

Expression of microRNAs was determined by TaqMan Low Density Array in H526 cells treated with valproic acid+VAC or VAC alone. For fold changes <0.5 or >2, the uncorrected p-value was <0.05 (common microRNAs when normalised to RNU44 and RNU48). NA: not applicable; VAC: mafosfamide, doxorubicin and vindesine.
SCLC (registered at www.elcwp.org with identifier number 01081). Results presented in the accompanying article by Berghmans et al. [26] indicate that the new regimen induces a significant response in relapsing/refractory SCLC patients. However, since the treatment does not translate into a significant progression-free survival, it is not recommended for second-line therapy.

Our transcriptomic data provide some evidence to better understand the mechanisms involved and to give insights for novel regimen. VPA modulates key genes modulating pathways linked to cell cycle and apoptosis. Among these, Puma (BC3C, Bcl-2 binding component 3), TNFRSF12A (TWEAK/Fn14), sodium/potassium ATPase and HEY1 (a mediator of Notch signalling) are significantly upregulated by VPA. In particular, the sodium/potassium ATPase is involved in sensitivity to platinium [27] and could be a major factor involved in VPA efficacy. Puma is able to interact with Bax and BclXL, promoting translocation of Bax to the mitochondria and competitive binding to BclXL, impeding the latter’s ability to inhibit Bax prosapopotic activity [28]. Parallel analyses of miRNA expression identified two particular miRNAs whose expression is tightly correlated with VPA treatment. When the VAC+VPA regimen is compared to VAC alone, miR-589 is increased 441-fold while miR-575 expression is reduced to 0.018. miRNA-589 modulates epithelial–mesenchymal transition in human mesothelial cells [29] while miR-575 promotes growth and invasion of lung cancer cells [30]. Causal involvement of these microRNAs in treatment efficacy could be further investigated by antagomiRs and miRNA mimics.

VPA also regulates expression of modulators of DNA damage response such as Bcl-6, which inhibits TP53 and modulates DNA damage-induced apoptotic responses [31]. Most important is the concomitant modulation of several genes involved in the Wnt pathway, including FZD2, FZD5, FZD7, FZD10 and WNT11. In this context, our preliminary data show that VPA activates TCF/LEF transcription factors in SCLC cells (data not shown). Furthermore, two general Wnt inhibitors (quercetin and ethacrynic acid) impair VPA-induced apoptosis. At first glance, involvement of Wnt in the therapeutic response may appear surprising, since this pathway has been directly correlated with tumorigenicity. For example, overexpression of FZD7 was associated with aberrant activation of the Wnt canonical pathway in oesophagus and colorectal cancers [32, 33]. However, the complexity of the Wnt pathways is clearly less well-understood or at least heterogenous in lung cancer [34]. In fact, expression of WNT7A, which targets FZD7, has been shown to be downregulated in lung cancer [35]. However, SCLC is characterised by overexpression of Wnt inhibitors such as NLK, Sox11 and TCF-4 [36]. In contrast, a tumour suppressor role of the Wnt pathway in SCLC has also been reported [37]. In this perspective, our results indicate that Wnt signalling is associated with a chemotherapeutic response. Similarly, there is a relationship between hyperinduced canonical Wnt activity and enhanced apoptosis in HDAC inhibitor-treated colorectal tumour cells [38].

In conclusion, this report provides preclinical insights for the use of VPA in second-line therapy of SCLC and opens new prospects for improvement using Wnt activators [39, 40].

Acknowledgements
We are grateful to Jean-Paul Sculier and Thierry Berghmans (Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles, Brussels, Belgium) for their collaboration in setting up the clinical trial reported in their companion article to this one [26]. We thank the GIGA technology platforms.

References
1 Amini A, Byers LA, Welsh JW, et al. Progress in the management of limited-stage small cell lung cancer. Cancer 2014; 120: 790–798.
2 Demedts IK, Vermaelen KY, van Meerbeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010; 35: 202–215.
3 Oze I, Hotta K, Kiura K, et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 2009; 4: e7835.
4 Rossi A, Maione P, Palazzolo G, et al. New targeted therapies and small-cell lung cancer. Clin Lung Cancer 2008; 9: 271–279.
5 Osterlind K. Chemotherapy in small cell lung cancer. Eur Respir J 2001; 18: 1026–1043.
6 Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25: 552–563.
7 Petta V, Gkiotas I, Strimpakos A, et al. Histones and lung cancer: are the histone deacetylases a promising therapeutic target? Cancer Chemother Pharmacol 2013; 72: 935–952.
8 Sasaki H, Moriyama S, Nakashima Y, et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004; 46: 171–178.
9 Schrump DS, Fischette MR, Nguyen DM, et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 2008; 14: 188–198.
10 Lecerq S, Gueugnon F, Boutin B, et al. A 5-aza-2’-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma. Eur Respir J 2011; 38: 1105–1116.
11 Scherperel A, Berghmans T, Lafitte J, et al. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 2011; 37: 129–135.
PUMA promotes Bax translocation by both directly interacting with Bax and by competitive binding to Bcl-X L during UV-induced apoptosis. Crit Rev Oncol Hematol 2010; 75: 173–174.

Zhang Y, Xing D, Liu L. PUMA promotes Bcl-X L inhibition and apoptosis of non-small cell lung cancer cells. J Toxicol Clin Toxicol 2009; 37: 25–42.

Spiller HA, Krenzelok EP, Klein-Schwartz W, Hubaux R, Thu KL, Coe BP, Achachi A, Florins A, Gillet N, Vandermeers F, Hubert P, Delvenne P, Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Hubaux R, Crisanti MC, Wallace AF, Kapoor V, Zhang Y, Xing D, Liu L. PUMA promotes Bax translocation by both directly interacting with Bax and by competitive binding to Bcl-X L during UV-induced apoptosis. Crit Rev Oncol Hematol 2010; 75: 173–174.

Spiller HA, Krenzelok EP, Klein-Schwartz W, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. J Toxicol Clin Toxicol 2000; 38: 755–760.

Crisanti MC, Wallace AF, Kapoor V, Zhang Y, Xing D, Liu L. PUMA promotes Bax translocation by both directly interacting with Bax and by competitive binding to Bcl-X L during UV-induced apoptosis. Crit Rev Oncol Hematol 2010; 75: 173–174.

Crisanti MC, Wallace AF, Kapoor V, Zhang Y, Xing D, Liu L. PUMA promotes Bax translocation by both directly interacting with Bax and by competitive binding to Bcl-X L during UV-induced apoptosis. Crit Rev Oncol Hematol 2010; 75: 173–174.